ABVC BioPharma Reports 230% Licensing Revenue Growth and Major Asset Expansion in Q3 2025

ABVC BioPharma, Inc. reported substantial financial growth for the third quarter of 2025, with licensing revenue increasing 230% year-over-year and total assets growing 181% since December 2024. The clinical-stage biopharmaceutical company recognized approximately $1.28 million in licensing revenue for Q3 2025 compared to $0.39 million for the same period in 2024, demonstrating significant momentum in its business development activities.

The company's total assets reached $21.18 million as of September 30, 2025, up from $7.54 million at the end of 2024. This substantial growth reflects ABVC's strategic shift toward physical asset investments, particularly in Taiwan, where property and equipment increased by approximately 2,100% to $12.06 million from just $0.51 million at year-end 2024. These investments represent a calculated expansion of the company's manufacturing and research capabilities in key Asian markets.

During the third quarter, ABVC completed two significant land acquisitions in Taiwan totaling approximately $11 million. AiBtl BioPharma Inc., a company affiliate, acquired property in Puli, Nantou for $7.67 million to develop a plant factory for botanical raw materials and new drug substance research. ABVC BioPharma itself invested $3.3 million in Longtan, Taoyuan for agricultural research and development and active pharmaceutical ingredient cultivation. These strategic moves, combined with the planned Vitargus® GMP manufacturing facility, are expected to significantly strengthen the company's Asia-based production and research infrastructure.

The company maintains a global dual-core operational structure, with Silicon Valley serving as the innovation and clinical development hub through its BioKey platform, while Taiwan supports manufacturing and development activities. This geographic diversification allows ABVC to leverage the strengths of both regions while mitigating operational risks. The company continues to pursue multiple licensing agreements covering its central nervous system, ophthalmology, and oncology pipelines, each providing potential future milestone and royalty income based on development and commercialization progress.

Dr. Uttam Patil, ABVC's Chief Executive Officer, stated that the third-quarter results reflect continued progress in both licensing revenue and asset development activities. The company remains focused on executing strategic priorities to create sustainable long-term value for shareholders. ABVC follows an asset-light business model centered on licensing, partnerships, and collaborative development, though recent investments in physical assets in Taiwan represent a strategic enhancement to future research and manufacturing capacity.

The company's pipeline includes six drugs and one medical device under development, with drug products utilizing in-licensed technology from prestigious research institutions including Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus®, the company intends to conduct pivotal clinical trials through global partnerships. Investors can access detailed company information through filings with the Securities and Exchange Commission available at https://www.sec.gov.

These developments position ABVC BioPharma for continued growth in the competitive biopharmaceutical landscape, with expanded manufacturing capabilities potentially accelerating drug development timelines and reducing production costs. The substantial increase in licensing revenue suggests growing industry interest in the company's therapeutic pipelines, while the strategic Taiwan investments provide a foundation for scalable manufacturing operations in a key global market.